Expression of glycosaminoglycans in cirrhotic liver and hepatocellular carcinoma—a pilot study including etiology

6Citations
Citations of this article
8Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Chronic liver diseases have both high incidence and mortality rates; therefore, a deeper understanding of the underlying molecular mechanisms is essential. We have determined the content and sulfation pattern of chondroitin sulfate (CS) and heparan sulfate (HS) in human hepatocellular carcinoma and cirrhotic liver tissues, considering the etiology of the diseases. A variety of pathological conditions such as alcoholic liver disease, hepatitis B and C virus infections, and primary sclerosing cholangitis were studied. Major differences were observed in the total abundance and sulfation pattern of CS and HS chains. For example, the 6-O-sulfation of CS is fundamentally different regarding etiologies of cirrhosis, and a 2–threefold increase in HS N-sulfation/O-sulfation ratio was observed in hepatocellular carcinoma compared to cirrhotic tissues. Graphical abstract: [Figure not available: see fulltext.]

Cite

CITATION STYLE

APA

Tóth, G., Pál, D., Sugár, S., Kovalszky, I., Dezső, K., Schlosser, G., … Turiák, L. (2022). Expression of glycosaminoglycans in cirrhotic liver and hepatocellular carcinoma—a pilot study including etiology. Analytical and Bioanalytical Chemistry, 414(13), 3837–3846. https://doi.org/10.1007/s00216-022-04025-3

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free